Eikon Therapeutics Updates Corporate Presentation with New Clinical Data and Milestones
EIKN sits 33% above its 52-week low of $7.9.
Summary
Eikon Therapeutics updated its corporate presentation with new clinical data from ASCO 2026 and reaffirmed multiple 2026 milestones across its oncology pipeline.
Key Events · Product Development and Regulatory · EIKN
-
Updated Corporate Presentation
Eikon furnished an updated corporate presentation (Exhibit 99.1) with Q3 2026 company update, including new clinical data and pipeline milestones.
-
EIK1001 NSCLC Data
TeLuRide-005 study showed ORR of 63.1% overall (55.6% NSQ, 72.4% SQ) and DCR of 90.8% overall, with median DOR >11 months in NSQ cohort.
-
EIK1003 PARP1 Data
Monotherapy ORR 14.3% (7/49) and paclitaxel combo ORR 24.5% (13/53); safety profile manageable with no treatment-related deaths.
-
EIK1005 WRN Inhibitor
Early clinical data: 23 subjects dosed, all AEs mild except one moderate, half-life 9.4 days, starting dose of 50mg established for Phase 1/2 trial.
Analysis · EIKN · Life Sciences
Eikon Therapeutics furnished an updated corporate presentation that includes detailed clinical data from its lead oncology programs. The presentation highlights encouraging efficacy for EIK1001 in NSCLC (63.1% ORR overall, 72.4% in squamous) and provides new safety data for EIK1003 and EIK1005. The company also reaffirmed multiple near-term milestones, including Phase 2 data readouts and an IND submission for EIK1006 by end of 2026. This update provides investors with the most current clinical snapshot and development timeline, which is material for a clinical-stage biotech.
At the time of this filing, EIKN was trading at $10.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $559.3M. The 52-week trading range was $7.90 to $17.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.